Skip to content

Clinical Study of Collateral Puncture Treatment for Erythematotelangiectatic Rosacea

Clinical Study of Collateral Puncture Treatment for Erythematotelangiectatic Rosacea

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2022000068
Enrollment
Unknown
Registered
2022-06-27
Start date
2022-09-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rosacea

Interventions

control group:intense pulsed light
treatment group:collateral puncture

Sponsors

Guang'anmen Hospital,China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.It meets the diagnostic criteria for rosacea in the Chinese rosacea diagnosis and treatment guidelines (2021 Edition), and belongs to erythematotelangiectatic rosacea; 2.Age 18 to 70 years (including 18 and 70 years); 3.Sign the informed consent form

Exclusion criteria

Exclusion criteria: 1.Patients with any systemic or active skin disease (such as connective tissue disease) that may affect the evaluation of experimental results on the face, or patients with scar, tattoo, birthmark or other pigmented skin disease on the affected part that may affect the evaluation of skin lesions; 2.Patients with serious primary diseases such as heart, cerebrovascular, liver, kidney or hematopoietic system, and patients with mental diseases or previous autoimmune diseases; Pregnant and lactating women; Photoallergic patients; Acupuncture syncope patients; 3.Within 30 days before treatment, oral immunomodulator (hydroxychloroquine sulfate tablets, etc.) ß Patients with rosacea related drugs such as adrenergic receptor inhibitors (carvedilol, etc.) and anti anxiety drugs (mirtazapine, paroxetine, etc.); 4.Patients who have used vasoconstrictors (0.5% bromonidine tartrate gel, 1% hydroxymethylzoline hydrochloride cream, etc.), calcineurin inhibitors, antibacterial agents and hormone ointment externally on the face within 7 days before treatment, and who have received fire acupuncture, bloodletting and LED light treatment on the face; 5.Patients who received facial injection, laser treatment and chemical exfoliation treatment within 30 days before treatment; 6.Patients who are participating in or have participated in other clinical trials within the last 3 months; 7.Patients who cannot tolerate any treatment in the test.

Design outcomes

Primary

MeasureTime frame
clinician's telangiectasia assessment;clinician's erythema assessment;

Secondary

MeasureTime frame
Dermatology Life Quality Index;rosacea quality of life index;investigator' s global assessment;patient' s self ? assessment;flushing assessment tool;

Countries

China

Contacts

Public ContactYan Yuhe

Guang'anmen Hospital,China Academy of Chinese Medical Sciences

yanyuhe5580@163.com13521665580

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026